The Europe Erythropoietin Drugs Market would witness market growth of 11.5% CAGR during the forecast period (2021-2027).
The market for Erythropoietin (EPO) Drugs is expected to grow in the forecast period. It is due to the increasing number of patients who are suffering from anaemia. The favourable reimbursements by the medical insurance companies as well as government and increasing commercialization of EPO drugs, and increasing occurrence of Chronic Kidney Diseases are some of the catalysts for the growth & demand for erythropoietin drugs.
Furthermore, the increasing prevalence of anaemic conditions due to end-stage renal disease treatment, chemotherapy in cancer, and antiretroviral treatment (ART) is the main factor that is likely to drive the growth of the erythropoietin market. Therefore, the number of treatment cycles for chemotherapy and rising incidences of end-stage renal diseases requiring dialysis have augmented demand for EPO.
Arterial hypertension, iron deficiency, and influenza-like syndrome, and a longer duration of EPO treatment (4-6 weeks) are some of the side effects of erythropoietin drugs. This aspect is expected to restrain the growth of the erythropoietin drug market. Although, the trends of commercialization for erythropoietin drugs are increasing, available reimbursements and favourable regulations by the government are leading to increased demand for erythropoietin drugs. Furthermore, increasing awareness among people about the benefits of EPO therapeutics is expected to boost the growth of the erythropoietin drugs market.
Erythropoietin Drugs Market is expected to grow at a significant rate in Europe. Erythropoietin is a hormone produced by the kidney and induces the formation of red blood cells in the bone marrow cells. They are used for the treatment of anaemia, HIV, and Cancer. Nowadays, due to advancements in recombinant DNA technology, several synthetic forms of erythropoietin are available in the market.
The increased occurrence of anaemia and favorable commercialization of EPO drugs in Europe is likely to boost the demand for Erythropoietin Drugs over the forecast period. The favourable reimbursement policies by the government are further driving the market growth. The availability of biosimilars in the market is expected to increase further during the forecast period.
The Germany market dominated the Europe Darbepoetin-alfa Market by Country in 2020, thereby, achieving a market value of $283.4 million by 2027. The UK market is exhibiting a CAGR of 11.2% during (2021 - 2027). Additionally, The France market is anticipated to witness a CAGR of 13.7% during (2021 - 2027).
Based on Drug Class, the market is segmented into Biologics and Biosimilars. Based on Product, the market is segmented into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others. Based on Application, the market is segmented into Renal Diseases, Cancer, Hematology and Neurology. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Erythropoietin Drugs Market Size will Hit $20.2 Billion by 2027, at a CAGR of 11.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson and Johnson, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd., Biocon Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., LG Corporation (LG Life Sciences Ltd.), and Celltrion, Inc.
By Drug Class
By Product
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
